True.
Still, none of the interested parties - management, original owners of the assets, and Xcel Capital - stand to gain if the share price remains below 3c.
They must have something up their sleeve.
The last announcement stated they have all the assay results in hand already and are reviewing it before releasing to the market. You would think (hope) it gets better than the first two.
